HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Axelsson, J. Articles by Stenvinkel, P. Search for Related Content PubMed PubMed Citation Articles by Axelsson, J. Articles by Stenvinkel, P. Agricola Articles by Axelsson, J. Articles by Stenvinkel, P.

Truncal fat mass as a contributor to inflammation in end-stage renal disease^1,2,3

¹ From the Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Karolinska Institutet, Karolinska University Hospital, Stockholm

² Supported by grants from the Karolinska Institutes Fund for Gender-based Research (to PS) and the Söderbergs Foundation (to PS).

³ Address reprint requests to P Stenvinkel, Division of Renal Medicine, K56, Karolinska University Hospital at Huddinge, 141 86 Stockholm, Sweden. E-mail: peter.stenvinkel{at}klinvet.ki.se.

	ABSTRACT

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Background: An activated inflammatory response is a common feature of end-stage renal disease (ESRD) and predicts outcome. Adipose tissue is an endocrine organ that may contribute to an inflammatory burden by secreting adipocytokines such as interleukin 6 (IL-6).

Objective: The objective was to relate plasma concentrations of IL-6 in ESRD patients to body composition, regional fat mass distribution, and blood lipid profiles.

Design: One hundred ninety-seven ESRD patients (123 men; ± SE age: 52 ± 1 y) were evaluated shortly before dialysis started. Lean body mass and truncal and nontruncal fat mass were estimated by dual-energy X-ray absorptiometry. Nutritional status was evaluated on the basis of subjective global assessment and handgrip strength. Inflammatory biomarker and blood lipid concentrations were also evaluated.

Results: Median IL-6 (8.5 compared with 4.5 pg/mL; P < 0.001) concentrations were significantly greater in malnourished than in well-nourished patients. Moreover, negative correlations were observed between IL-6 and serum creatinine ( = –0.19, P < 0.01), handgrip strength ( = –0.24, P < 0.001), and serum albumin ( = –0.34, P < 0.001). A significantly higher truncal fat mass (12.8 ± 0.7 compared with 10.5 ± 0.4 kg; P < 0.005) was observed in ESRD patients with inflammation (C-reactive protein 10 mg/L). Inverse correlations were observed between plasma IL-6 and HDL cholesterol ( = –0.16, P < 0.05) and apolipoprotein A ( = –0.23, P < 0.001).

Conclusions: Plausible relations exist between inflammatory biomarkers, such as IL-6 and high-sensitivity C-reactive protein, and regional fat distribution in ESRD patients. Moreover, the strong inverse relations between HDL cholesterol and apolipoprotein A and biomarkers of inflammation suggest that the chronic inflammatory response observed in ESRD patients is an important contributor to the atherogenic lipoprotein profile in uremia.

Key Words: Inflammation • cytokines • fat mass • body composition • malnutrition • cholesterol • end-stage renal disease

	INTRODUCTION

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Human adipose tissue was recently shown to be a hormonally active system that secretes various adipocytokines, such as leptin, interleukin 6 (IL-6), tumor necrosis factor (TNF-), resistin, plasminogen activator inhibitor, adiponectin, and serum amyloid A (1-4). Additionally, the hormonal activity of adipose tissue is thought to differ according to body location. Intraperitoneal (truncal) fat is the most hormonally active adipose tissue and plays an important role in the development of insulin resistance, type 2 diabetes, and premature atherosclerosis (5, 6). It is well known that an elevated serum IL-6 concentration is predictive of future cardiovascular problems (7, 8), and body adipose tissue may account for as much as 20% of systemic IL-6 concentrations (1). Indeed, a functional and molecular overlap between fat cells and macrophages was recently reported (9).

The quantity and distribution of body adipose tissue are also related to the blood lipid profile (10), and studies have shown independent negative associations between inflammatory biomarkers and serum HDL and LDL particles (11, 12), which have also been shown to modulate the immune response through the binding and inactivation of endotoxins (13).

These observations are of special interest in the management of patients with end-stage renal disease (ESRD), in whom serologic evidence of an activated inflammatory response [on the basis of C-reactive protein (CRP) concentrations] exists in 30–50% of European and North American predialysis, hemodialysis, and peritoneal dialysis patients and is a powerful predictor of outcome and cardiovascular disease (14). Because the hepatic synthesis of CRP is largely under the regulation of IL-6, it is not surprising that the activity of this cytokine also is markedly up-regulated in ESRD patients (15) or that elevated plasma IL-6 concentrations are associated with a higher mortality rate in ESRD patients (15-17). The causes of elevated plasma concentrations of IL-6 in ESRD are multifactorial and only partly elucidated, but they may include the uremic syndrome (18), age (19), chronic heart failure (20), persistent infections (21, 22), and the bioincompatibility of the dialyzer membrane and endotoxin absorption from contaminated dialysate or from the gut (14).

Considering these findings and those of recent studies in the general population that link obesity with the presence of low-grade systemic inflammation (23, 24), we hypothesize that body fat mass (FM) and distribution may influence the systemic inflammation of ESRD. The objective of the present study was thus to relate plasma concentrations of IL-6 in ESRD patients to their body composition, regional FM distribution, and blood lipid profile.

	SUBJECTS AND METHODS

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Patients
One hundred ninety-seven ESRD patients (123 men; 62%) with a mean age of 52 ± 1 y were evaluated shortly before the beginning of dialysis (glomerular filtration rate: 7 ± 1 mL/min). They were selected from an ongoing prospective study, and part of this patient material was previously described (18, 25). The study exclusion criteria were as follows: age > 70 y, malignancy, overt infectious complications, and unwillingness to participate in the study. The Ethics Committee of the Karolinska Institute approved the study protocol at Huddinge University Hospital, Stockholm, and informed consent was obtained from the patients. On the basis of subjective global assessment (SGA), 65 patients (33%) were characterized as malnourished (SGA > 1), whereas 132 patients were characterized as well-nourished. Fifty-six patients (28%) had type 1 or 2 diabetes mellitus. Most patients were taking antihypertensive medications as well as other drugs commonly used in ESRD, such as phosphate and potassium binders, diuretics, and supplements of vitamins B, C, and D.

Methods
After the subjects fasted overnight, venous blood samples were taken for analysis. The samples were kept frozen at –70 °C if not analyzed immediately. The glomerular filtration rate, estimated as the mean of urea and creatinine clearance, was calculated from 24-h urinary samples collected from 179 of the patients. Plasma IL-6 was analyzed by enzyme-linked immunosorbent assay (Boehringer Mannheim, Mannheim, Germany). The sensitivity was 75 pg/mL, intraassay CV was 3%, interassay CV was 6%, and correlation (R²) between repeated measurements was 0.93. High sensitivity (hs) CRP was measured by using nephelometry (n = 157), whereas the white blood cell (WBC) count (n = 151), fibrinogen (n = 157), and serum albumin (bromcresol purple) were measured by using routine methods at the Department of Clinical Chemistry, Huddinge University Hospital. The concentrations of serum cholesterol and triacylglycerols were analyzed by using standard enzymatic procedures (Boehringer Mannheim). HDL cholesterol was determined after precipitation of apo B–containing lipoproteins by phosphotungstic acid. Concentrations of apolipoprotein A-I (apo A) and apo B were determined by using an immunonephelometric procedure (Behring AG, Marburg, Germany). Handgrip strength (HGS) was evaluated in both the dominant and nondominant arms by using the Harpenden Handgrip Dynamometer (Yamar, Jackson, MI). The HGS measurement was repeated 3 times, and the highest value was noted. Subjective global assessment (SGA) was used to obtain an overall clinical estimate of malnutrition as previously described (26). Lean body mass (LBM) and total FM were estimated by dual-energy X-ray absorptiometry (DXA) with the use of the DPX-L device (Lunar Corp, Madison, WI). Regional estimations of truncal arm and leg FM were performed in all patients with the use of the same method. With this technique, fat and LBM distribution are directly estimated without making assumptions about the 2-compartment model. DXA has proved superior to other simple noninvasive methods for determining body composition in renal failure, especially if repeated measurements are made (27). However, it must be kept in mind that, although the state of hydration does not affect the estimate of FM with DXA, it does affect the estimate of LBM.

Statistical analysis
Results are expressed as means ± SEs, unless otherwise indicated. P values < 0.05 indicated significance. Comparisons between 2 groups were made by using Student’s t test or Mann-Whitney’s U test as appropriate. Comparisons of nominal variables between groups were made by chi-square test. Because most values were not normally distributed, correlations between variables were calculated with the use of Spearman’s test. A three-factor multivariate analysis of variance with Wilk’s lambda was used to measure the degree of correlation between variables. The model included a test for the effect of order. The general linear model procedure with least-squares means was used to identify significant interactions between factors. When significant interactions were found between factors (A x B), they were identified with simple main effects tests. Stepwise multivariate regression analysis was used to assess the predictors for log IL-6. All analyses were performed by using statistical software SAS (version 8.2; SAS Campus Drive, Cary, NC).

	RESULTS

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Clinical characteristics, nutritional status, and body composition
Basal clinical characteristics and nutritional and body-composition data of the 197 ESRD patients close to the start of dialysis are given in Table 1. The patients were divided into 8 groups by sex, nutritional status, and inflammatory status. As expected, significant differences in body composition were noted between the 2 sexes. Compared with the men, the women had a higher body FM content (23.1 ± 1.0 compared with 19.4 ± 0.8 kg; P < 0.01) and a lower LBM (39.5 ± 0.8 compared with 54.8 ± 0.6 kg; P < 0.001). However, whereas a marked difference in nontruncal FM was observed between women and men (10.1 ± 0.4 and 7.3 ± 0.3 kg, respectively; P < 0.001), we found no significant difference in truncal FM between the women and men (11.6 ± 0.5 compared with 10.9 ± 0.4 kg, respectively). Whereas marked differences in serum creatinine concentrations (8.7 ± 0.2 and 6.7 ± 0.2 mg/dL, respectively; P < 0.0001) and in HGS (36 ± 1 and 24 ± 1 kg, respectively; P < 0.0001) were shown between the men and women, no significant differences in inflammatory biomarkers were noted between the sexes.

The presence of inflammation (CRP 10 mg/L) was associated with body composition (Table 1). Whereas the 63 patients with inflammation had higher total body (23.2 ± 1.1 compared with 19.6 ± 0.7 kg; P < 0.01) and truncal (12.8 ± 0.7 compared with 10.5 ± 0.4 kg; P < 0.005) FM than did the 134 patients with no inflammation, no significant difference in LBM was observed between the 2 groups. Moreover, whereas patients with inflammation had significantly lower total cholesterol (5.4 ± 0.2 compared with 5.7 ± 0.1 mmol/L; P < 0.05), HDL-cholesterol (1.05 ± 0.06 compared with 1.37 ± 0.04 mmol/L; P < 0.001), and apo A (1.18 ± 0.04 compared with 1.40 ± 0.03 g/L; P < 0.001) concentrations, no significant differences in triacylglycerols or apo B concentrations were observed.

Relation between inflammatory biomarkers and nutritional status and body composition
Median IL-6 concentrations did not differ significantly between the diabetic (6.1 pg/mL) and nondiabetic (5.6 pg/mL) subjects or between men (5.4 pg/mL) and women (6.2 pg/mL). As expected, IL-6 was significantly positively correlated with age ( = 0.49, P < 0.001), hs-CRP ( = 0.60, P < 0.001), WBC ( = 0.24; P < 0.01), and fibrinogen ( = 0.34; P < 0.001). All correlations between the 4 inflammatory biomarkers (IL-6, hs-CRP, WBC, and fibrinogen) and the nutritional and body-composition data are given in Table 2. Of note, negative correlations were observed between IL-6 and the nutritional markers serum creatinine ( = –0.19, P < 0.01), HGS ( = –0.24, P < 0.001), and serum albumin ( = –0.34, P < 0.001). The correlation between IL-6 and HGS is depicted in Figure 1. No significant correlations were observed between hs-CRP or IL-6 and LBM.

View larger version (23K): [in this window] [in a new window]   FIGURE 1. Relation between handgrip strength (a surrogate marker of muscle mass) and the proinflammatory cytokine interleukin 6 in 185 patients with end-stage renal disease shortly before dialysis treatment began. • = female; = male.

Figure 2

View larger version (15K): [in this window] [in a new window]   FIGURE 2. Relations between serum concentrations of the proinflammatory cytokine interleukin 6 and truncal and nontruncal fat mass in 197 patients with end-stage renal disease shortly before dialysis treatment began. The relations suggest a fundamental difference in the association between interleukin 6 and truncal (ie, visceral) and nontruncal (ie, subcutaneous) fat tissue depots in uremia. • = female; = male.

Table 3

Figure 3

View larger version (15K): [in this window] [in a new window]   FIGURE 3. Relations between HDL-associated apolipoprotein A and serum concentrations of the proinflammatory cytokine interleukin 6 (n = 197) and the acute phase reactant high-sensitivity C-reactive protein (n = 157) in patients with end-stage renal disease shortly before dialysis treatment began. The data indicate an association between the atherogenic lipid profile found in uremia and the presence of inflammation. • = female; = male.

	DISCUSSION

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

It is notable that the relation between FM and inflammatory biomarkers seemed to differ between truncal and nontruncal FM. Truncal FM is closely related to visceral FM, which is the fat-tissue depot considered to be the most metabolically active and that has been identified as a key factor in the development of insulin resistance, type 2 diabetes, and premature atherosclerosis (5, 6). Importantly, visceral and subcutaneous adipose tissue depots are biologically distinct (35), and omental adipose tissue releases 2–3 times the amount of IL-6 than does subcutaneous fat tissue (36). Clearly, in future studies evaluating BMI and obesity as risk factors for outcome, inflammation, and cardiovascular events in ESRD patients, a distinction between FM of visceral and subcutaneous origin should be made.

Several studies have shown that inflammatory biomarkers, such as CRP (37), WBC (38), fibrinogen (39), and IL-6 (15-17), are strong independent predictors of all-cause and cardiovascular mortality in ESRD patients. This suggests that inflammation plays a pivotal role in the development of both malnutrition and atherosclerosis (malnutrition, inflammation, and atherosclerosis hypothesis; 40) in this patient group. IL-6, especially, has been speculated to play a central role in the loss of muscle mass (sarcopenia), which is often observed in ESRD patients (28). In the present study, clinical nutritional status (SGA) and surrogate markers of muscle protein stores (HGS and serum creatinine) were correlated with plasma IL-6, which indicates an important role for this cytokine in the development of protein malnutrition and muscle catabolism in ESRD. A relation between protein malnutrition and elevated concentrations of IL-6 was previously described in elderly nonrenal patients by Visser et al (41). They found that higher serum concentrations of IL-6 and TNF- correlated with decreased muscle mass and muscle strength independently of race and sex. Moreover, increased concentrations of IL-6 are associated with various markers of malnutrition in cross-sectional analyses (15, 42). In older patients without renal disease, cachexia is usually associated with higher-than-normal concentrations of TNF-, IL-1, and IL-6 (43, 44). An important role for IL-6 in this scenario could be proposed as it stimulates the breakdown of muscle protein (44) and promotes cancer cachexia (45). Treatment with IL-6 receptor antibody has been shown to inhibit muscle atrophy in IL-6 transgenic mice (46). Moreover, because IL-6 inhibits the secretion of insulin-like growth factor I (IGF-I), the negative effect of IL-6 on muscle function and strength may be mediated via IGF-I (47).

Whereas hypercholesterolemia is a well-established risk factor for cardiovascular mortality and morbidity in the general population, hypocholesterolemia is associated with a significantly higher risk of death in ESRD patients, a phenomenon termed "reverse epidemiology" (48). A recent study by Liu et al (49) showed that the inverse association of total cholesterol concentrations with mortality is due to the cholesterol-lowering effects of systemic inflammation and malnutrition in dialysis patients. Indeed, chronic IL-6 injections have been shown to cause acquired hypocholesterolemia and weight loss in nonhuman primates (50). Additionally, it is possible that HDL or its associated apo A may have specific antiinflammatory effects due to an ability to bind and inactivate endotoxins (51, 52), decreasing the amount available to bind to cell surface Toll-like receptor 4, either directly or via cell membrane CD14 (53), and thus modulating the immunologic response. Inverse correlations between inflammatory biomarkers and total serum cholesterol were previously shown in both nonrenal (11) and renal (49) patients. The present study showed significant inverse correlations between inflammatory biomarkers and total cholesterol, HDL cholesterol, and apo A concentrations (Figure 3), which supports the link between cholesterol metabolism and chronic inflammation.

It may seem paradoxical that we found associations between plasma IL-6 concentrations and both increased FM (indicating adequate energy stores) and surrogate markers of sarcopenia (indicating protein malnutrition). However, the processes of protein and energy malnutrition may not always evolve simultaneously. Thus, the presence of obesity and increased truncal FM may not necessarily imply adequate protein intake and nutritional status. Indeed, we (H Honda, AR Qureshi, O Heimbürger et al, unpublished observations, 2004) found markedly elevated plasma IL-6 concentrations in malnourished (on the basis of the SGA) ESRD patients with both high (>25) and low (<20) BMIs. Actually, it could be speculated that the enhanced generation of proinflammatory cytokines (such as IL-1 and IL-6), resulting from increased truncal FM, may be an important factor that contributes to the sarcopenia often encountered in chronic nonmalignant disorders and aging. Thus, in cross-sectional studies such as this, the true associations between IL-6 and body composition may not be evident because ESRD patients with a wide range of comorbid conditions and differences in the duration of disease and age are studied. Clearly, long-term prospective studies are needed to evaluate the evolution of inflammatory biomarkers and their relation to changes in regional body composition as renal function declines.

Some limitations of the present study should be considered. First, because the study was based on a cross-sectional and post hoc evaluation of a heterogeneous group of patients, the associations between inflammatory biomarkers and body composition may be obscured by many factors not controlled for in the present study, such as age, comorbidity, and duration of kidney disease. In addition, only one single measurement of hs-CRP and IL-6 was used in the present study, even though inflammatory biomarkers may vary with time. Furthermore, this study did not measure sex hormone concentrations (particularly testosterone), which are known to suppress the activation of proinflammatory cytokines (54). Moreover, there remains the possibility that had we studied prevalent patients with a dialysis time of more than a few months, truncal FM might have had an even more significant influence. Also, although the present study included 197 patients, size and a heterogeneous population may still limit it, making it difficult to draw clear conclusions. Finally, it should be emphasized that plasma inflammatory biomarkers may not adequately reflect local fat tissue inflammation (55).

In conclusion, the present cross-sectional study showed a relation between systemic inflammation (on the basis of measured IL-6) and regional fat distribution in ESRD patients and also showed the existence of inverse relations between cholesterol, HDL cholesterol, and apo A and markers of inflammation in these patients. We speculate that a chronic inflammatory response, partly related to truncal FM, may be a part of the metabolic syndrome and may contribute to the atherogenic lipoprotein profile and to the loss of muscle mass in ESRD.

	ACKNOWLEDGMENTS

 
JA, BL, OH, and PS were responsible for the study design. JA and PS wrote most of the final manuscript. OH and PS were involved in the patient recruitment and data collection. JA, PS, and ARQ performed the statistical calculations. MES, HH, TC, and RP-F conducted the serum measurements and helped interpret the data. BL is affiliated with Baxter Healthcare Inc.

	REFERENCES

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.[Abstract/Free Full Text]
2. Wiecek A, Kokot F, Chudek J, Adamczak M. Adipose tissue—a novel endocrine organ of interest for the nephrologist. Nephrol Dial Transplant 2002;17:191-5.
3. Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 2002;51:1876-83.[Abstract/Free Full Text]
4. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001;276:42077-83.[Abstract/Free Full Text]
5. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci 2003;24:276-83.[Medline]
6. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003;14:137-45.[Medline]
7. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88:10K-5K.[Medline]
8. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92:17K-22K.[Medline]
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.[Medline]
10. Van Gaal L, Vansant G, Van Campenhout C, Lepoutre L, De Leeuw I. Apolipoprotein concentrations in obese subjects with upper and lower body fat mass distribution. Int J Obes 1989;13:255-63.[Medline]
11. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003;167:73-9.[Medline]
12. Irish A. Cardiovascular disease, fibrinogen and the acute phase response. Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133-9.[Medline]
13. Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999;274:34116-22.[Abstract/Free Full Text]
14. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329-37.[Medline]
15. Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-8.[Abstract/Free Full Text]
16. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-14.[Medline]
17. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236-44.[Medline]
18. Pecoits-Filho R, Heimbürger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-8.[Medline]
19. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA. Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 1998;53:M20-6.
20. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.[Abstract/Free Full Text]
21. van Tellingen A, Grooteman MP, Schoorl M, et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002;62:632-8.[Medline]
22. De Marchi S, Falleti E, Giacomello R, et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 1996;7:1169-77.[Abstract]
23. Pedersen M, Bruunsgaard H, Weis N, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Aging Dev 2003;124:495-502.
24. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-9.[Abstract/Free Full Text]
25. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.[Medline]
26. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987;33:650-3.
27. Kerr PG, Strauss BJG, Atkins RC. Assessment of the nutritional state of dialysis patients. Blood Purif 1996;14:382-7.[Medline]
28. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition and atherosclerosis in end-stage renal disease: what is the role of interleukin-6? Kidney Int 2002;61:S103-8.
29. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998;31:93-100.[Medline]
30. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19:53-61.[Medline]
31. Stompor T, Rajzer M, Sulowicz W, et al. An association between aortic pulse wave velocity, blood pressure and chronic inflammation in ESRD patients on peritoneal dialysis. Int J Artif Organs 2003;26:188-95.[Medline]
32. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-6.[Medline]
33. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-8.
34. Gallistl S, Sudi KM, Aigner R, Borkenstein M. Changes in serum interleukin-6 concentrations in obese children and adolescents during a weight reduction program. Int J Obes Relat Metab Disord 2001;25:1640-3.[Medline]
35. Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N. Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 2002;34:622-8.[Medline]
36. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50.[Abstract/Free Full Text]
37. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58.[Medline]
38. Reddan DN, Klassen PS, Szczech LA, et al. White blood cells as a novel predictor in haemodialysis patients. Nephrol Dial Transplant 2003;18:1167-73.[Abstract/Free Full Text]
39. Zoccali C, Mallamaci F, Tripepi G, et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Int Med 2003;254:132-9.[Medline]
40. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-60.
41. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002;57:M326-32.[Abstract/Free Full Text]
42. King AJ, Kehayias JJ, Roubenoff R, Schmid CH, Pereira BJ. Cytokine production and nutritional status in hemodialysis patients. Int J Artif Organs 1998;21:4-11.[Medline]
43. Yeh SS, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr 1999;70:183-97.[Abstract/Free Full Text]
44. Cederholm T, Wretlind B, Hellstrom K, et al. Enhanced generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease. Am J Clin Nutr 1997;65:876-82.[Abstract/Free Full Text]
45. Argiles JM, Busquets S, Lopez-Soriano FJ. Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 2003;6:401-6.[Medline]
46. Tsujinaka T, Fujita J, Ebisui C, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996;97:244-9.[Medline]
47. Barbieri M, Ferrucci L, Ragno E, et al. Chronic inflammation and the effect of IGF-1 on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003;284:E481-7.[Abstract/Free Full Text]
48. Kalantar-Zadeh K, Block G, Humphries MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.[Medline]
49. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9.[Abstract/Free Full Text]
50. Ettinger WH, Sun WH, Binkley N, Kouba E, Ershler W. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol A Biol Sci Med Sci 1995;50:M137-40.
51. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994;180:1025-35.[Abstract/Free Full Text]
52. Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381-9.[Abstract/Free Full Text]
53. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000;12:20-6.[Medline]
54. Kanda N, Tsuchida T, Tamaki K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol 1996;106:410-5.[Medline]
55. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-6.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. Axelsson The emerging biology of adipose tissue in chronic kidney disease: from fat to facts Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3041 - 3046. [Full Text] [PDF]

				P. K.-T. Li, B. C.-H. Kwan, C. C. Szeto, and G. T.-C. Ko Metabolic syndrome in peritoneal dialysis patients NDT Plus, August 1, 2008; 1(4): 206 - 214. [Abstract] [Full Text] [PDF]

				T. A. Ikizler, P. Stenvinkel, and B. Lindholm Resolved: Being Fat Is Good for Dialysis Patients: The Godzilla Effect: Pro J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1059 - 1064. [Abstract] [Full Text] [PDF]

				J. C K Wells and M. S Fewtrell Is body composition important for paediatricians? Arch. Dis. Child., February 1, 2008; 93(2): 168 - 172. [Abstract] [Full Text] [PDF]

				R. Agarwal, M. J. Andersen, and J. H. Pratt On the Importance of Pedal Edema in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 153 - 158. [Abstract] [Full Text] [PDF]

				M L. Trirogoff, A. Shintani, J. Himmelfarb, and T A. Ikizler Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3 4 chronic kidney disease patients Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1642 - 1648. [Abstract] [Full Text] [PDF]

				B. C.H. Kwan, M. A. Murtaugh, and S. Beddhu Associations of Body Size with Metabolic Syndrome and Mortality in Moderate Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 992 - 998. [Abstract] [Full Text] [PDF]

				M. A. Kamimura, S. A. Draibe, M. A. Dalboni, M. Cendoroglo, C. M. Avesani, S. R. Manfredi, M. E. F. Canziani, and L. Cuppari Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure Nephrol. Dial. Transplant., March 1, 2007; 22(3): 839 - 844. [Abstract] [Full Text] [PDF]

				R. de Mutsert, M. B. Snijder, F. van der Sman-de Beer, J. C. Seidell, E. W. Boeschoten, R. T. Krediet, J. M. Dekker, J. P. Vandenbroucke, F. W. Dekker, and for the Netherlands Cooperative Study on the Adequ Association between Body Mass Index and Mortality Is Similar in the Hemodialysis Population and the General Population at High Age and Equal Duration of Follow-Up J. Am. Soc. Nephrol., March 1, 2007; 18(3): 967 - 974. [Abstract] [Full Text] [PDF]

				X. Wang, J. Axelsson, L. Nordfors, A. R. Qureshi, C. Avesani, P. Barany, M. Schalling, O. Heimburger, B. Lindholm, and P. Stenvinkel Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism Nephrol. Dial. Transplant., January 1, 2007; 22(1): 196 - 202. [Abstract] [Full Text] [PDF]

				K. Kalantar-Zadeh, N. Kuwae, D. Y Wu, R. S Shantouf, D. Fouque, S. D Anker, G. Block, and J. D Kopple Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients Am. J. Clinical Nutrition, February 1, 2006; 83(2): 202 - 210. [Abstract] [Full Text] [PDF]

				S. Beddhu, N. Ramkumar, and M. H Samore The paradox of the "body mass index paradox" in dialysis patients: associations of adiposity with inflammation Am. J. Clinical Nutrition, October 1, 2005; 82(4): 909 - 910. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Axelsson, J. Articles by Stenvinkel, P. Search for Related Content PubMed PubMed Citation Articles by Axelsson, J. Articles by Stenvinkel, P. Agricola Articles by Axelsson, J. Articles by Stenvinkel, P.